Drugs / DT2-SCT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06789302 | Dec 2025 → Jun 2028 expected | type 2 diabetes mellitus | Global Institute of Stem Cell Therapy and Research | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT2-SCT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06789302 ↗ |
| Modality | Cell therapy | “autologous adipose-derived mesenchymal stem cell (MSC) therapy” NCT06789302 ↗ |
| Route | Intravenous | “The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour.” NCT06789302 ↗ |